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kinase which phosphorylates and activates protein kinase Ba
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Background: Protein kinase B (PKB), also known as c-Akt, is activated rapidly
when mammalian cells are stimulated with insulin and growth factors, and much
of the current interest in this enzyme stems from the observation that it lies
‘downstream’ of phosphoinositide 3-kinase on intracellular signalling pathways.
We recently showed that insulin or insulin-like growth factor 1 induce the
phosphorylation of PKB at two residues, Thr308 and Ser473. The
phosphorylation of both residues is required for maximal activation of PKB. The
kinases that phosphorylate PKB are, however, unknown.
Results: We have purified 500 000-fold from rabbit skeletal muscle extracts a
protein kinase which phosphorylates PKBa at Thr308 and increases its activity
over 30-fold. We tested the kinase in the presence of several inositol
phospholipids and found that only low micromolar concentrations of the D
enantiomers of either phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3)
or PtdIns(3,4)P2 were effective in potently activating the kinase, which has been
named PtdIns(3,4,5)P3-dependent protein kinase-1 (PDK1). None of the inositol
phospholipids tested activated or inhibited PKBa or induced its phosphorylation
under the conditions used. PDK1 activity was not affected by wortmannin,
indicating that it is not likely to be a member of the phosphoinositide 3-kinase
family. 
Conclusions: PDK1 is likely to be one of the protein kinases that mediate the
activation of PKB by insulin and growth factors. PDK1 may, therefore, play a key
role in mediating many of the actions of the second messenger(s)
PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2.
Background
Protein kinase B (PKB) [1], or RAC protein kinase [2], is
the cellular homologue of a viral oncogene v-Akt [3] and
has therefore also been termed c-Akt. The current inter-
est in PKB stems firstly from the discovery that it is acti-
vated rapidly in response to insulin and growth factors and
that this activation is prevented by inhibitors of
phosphoinositide (PI) 3-kinase [4–6], and secondly from
the finding that PKB isoforms are overexpressed in a
significant percentage of ovarian, pancreatic [7,8] and
breast cancer cells [2].
PKB appears to mediate the insulin-induced inhibition of
glycogen synthase kinase-3 (GSK3) in L6 cultured
myotubes; this inhibition is thought to underlie, at least in
part, the insulin-induced dephosphorylation and activa-
tion of glycogen synthase [9] and protein synthesis initia-
tion factor eIF2 [10] that contribute to the stimulation of
glycogen and protein synthesis by insulin. PKB is likely to
have other physiological substrates, however, and in trans-
fection experiments it has been shown to activate p70 S6
kinase [5], to stimulate the translocation of the glucose
transporter GLUT4 to the plasma membrane and enhance
glucose uptake in 3T3-L1 adipocytes [11], and to mediate
the survival of neurones [12] and fibroblasts [13] induced
by insulin-like growth factor 1 (IGF1). 
A critical question concerns the mechanism by which PI 3-
kinase triggers the activation of PKB. Activation of PKB is
accompanied by its phosphorylation [5,14], and we have
recently shown that activation by insulin or IGF1 results
from phosphorylation of PKB at two residues, Thr308 and
Ser473 [15]. Moreover, the insulin-induced or IGF1-
induced phosphorylation of both residues is abolished by
wortmannin, an inhibitor of PI 3-kinase [15]. These find-
ings suggest that the protein kinase(s) which phosphory-
late PKB at Thr308 and Ser473 might themselves be
activated by phosphatidylinositol 3,4,5 trisphosphate
(PtdIns(3,4,5)P3), the product of the reaction catalyzed by
PI 3-kinase. In this paper, we demonstrate that this is
indeed the case, and report the purification and initial
characterization of a 3-phosphoinositide-dependent prot-
ein kinase, PDK1, which activates PKB by phosphorylat-
ing it at Thr308.
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Results
Purification of GST–PKBa from 293 cells 
PKBa was expressed in human embryonic kidney 293
cells as a fusion protein with glutathione S-transferase
(GST) attached at its amino terminus, and purified on
glutathione–Sepharose beads. The preparation showed a
major protein band that stained with Coomassie blue, of
apparent molecular mass 85 kDa, corresponding to
GST–PKBa (Fig. 1). The purity estimated by densito-
metric analysis of the gels was more than 70% and 2 mg of
purified GST–PKBa was obtained routinely in each
preparation made from forty 10 cm diameter dishes of 293
cells. GST–PKBa from unstimulated 293 cells had a very
low activity, but it was activated 20-fold and 45-fold after
stimulation of 293 cells with insulin and IGF1 (data not
shown), respectively, indicating that it is recognized by
the upstream protein kinase(s) that activate PKBa in vivo.
GST–PKBa from unstimulated 293 cells was therefore
used as the substrate with which to identify upstream
activators.
Identification of a PtdIns(3,4,5)P3-dependent protein
kinase that activates PKBa
We identified an activator of GST–PKBa in skeletal
muscle cytosol that eluted from a QAE–Sephadex column
at 0.25 M salt, and we purified it a further 30 000-fold from
the QAE–Sephadex eluate (Table 1 and Fig. 2). The acti-
vator was completely dependent on PtdIns(3,4,5)P3 for
activity, and, because it phosphorylates PKBa (see below),
it is hereafter termed PtdIns(3,4,5)P3-dependent protein
kinase-1 (PDK1). 
PDK activity could not be detected in the crude cytosol,
but assuming a recovery of 50% through the initial batch-
wise chromatography on QAE–Sephadex, the overall purifi-
cation was about 500 000-fold, and the entire preparation
procedure could be completed within 36 hours. PDK activ-
ity eluted as a single peak from SP-Sepharose (Fig. 2a), but
resolved into two peaks on heparin–Sepharose (Fig. 2b); the
minor component (peak 1) eluted at 0.5 M NaCl and the
major component (peak 2) at 0.7 M NaCl. All further exper-
iments were carried out with the PDK activity of peak 2
further purified through Mono S (Fig. 2c), unless stated
otherwise. After the final purification step, the active frac-
tion, which was devoid of PKB activity, comprised three
major protein bands, with apparent molecular masses of 85,
67 and 45 kDa (data not shown). Only the 67 kDa band
became phosphorylated upon incubation with Mg–ATP
and phosphorylation was greatly increased in the presence
262 Current Biology, Vol 7 No 4
Figure 1
SDS–polyacrylamide gel of purified GST–PKBa. Human 293 cells were
transiently transfected with the pEBG2T DNA construct expressing
GST–PKBa, serum starved for 16 h and, after cell lysis, GST–PKBa
was purified by affinity chromatography on glutathione–Sepharose (see
Materials and methods). The glutathione–Sepharose eluate (3mg
protein) was electrophoresed on a 10% SDS–polyacrylamide gel and
stained with Coomassie blue. The position of the molecular mass
markers glycogen phosphorylase (97 kDa), bovine serum albumin
(66 kDa) and ovalbumin (43 kDa) are indicated.
97
kDa
66
43
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Table 1
Purification of PDK1 from rabbit skeletal muscle. 
Step Volume Protein Activity Specific activity Purification Yield
(ml) (mg) (U) (U mg–1) (fold) (%)
1. Extract 1 400 17 000 Not measurable – – –
2. QAE–Sephadex 750 555 1 330 2.4 1 100
3. 4–15% PEG 55 164 1 190 7.3 3 89
4. SP–Sepharose 88 10 610 61 25 46
5. Heparin–Sepharose 11 0.01 290 29 000 12 000 22
6. Mono S 0.3 0.002 139 69 500 29 000 10
The amount of muscle used in this preparation was 500 g; the amount of protein at each step was estimated by the procedure of Bradford [28].
PEG is polyethyleneglycol.
of PtdIns(3,4,5)P3 (data not shown). The amino-acid
sequences of two tryptic peptides from the 67 kDa band
were highly homologous to regions of the catalytic domains
of other protein kinases (data not shown). The data indicate
that PDK1 is a newly identified 67 kDa protein kinase, dis-
tinct from other protein kinases that have been reported to
be activated by PtdIns(3,4,5)P3, such as PKCe and PKCz.
Phosphorylation and activation of GST–PKBa by PDK1 
Purified PDK1 phosphorylated GST–PKBa in the pres-
ence of Mg–ATP and phospholipid vesicles containing
phosphatidylcholine (PtdCho), phosphatidylserine (PtdSer)
and PtdIns(3,4,5)P3, to a level approaching 0.7 moles of
incorporated phosphate per mole of protein (Fig. 3a). Phos-
phorylation of GST–PKBa was paralleled by an increase in
its activity of over 30-fold (Fig. 3a) to a specific activity of
80 U mg–1. This is similar to the specific activity of PKBa
that has been partially activated by a Thr308→Asp muta-
tion [15,16]. Omitting either PtdIns(3,4,5)P3, PDK1 or ATP
from the reaction abolished activation and phosphorylation
of GST–PKBa (Fig. 3b). Moreover, addition of 0.5% (by
volume) Triton X-100 to the assays also prevented the acti-
vation and phosphorylation of GST–PKBa by PDK1 (Fig.
3b), as did incubating PDK1 for 2 minutes at 55°C. In the
absence of PtdCho/PtdSer vesicles, PtdIns(3,4,5)P3 was at
least 15-fold less effective in activating PDK1 (Fig. 3b). 
When PDK1 was incubated for 30 minutes at 30°C in the
presence of phospholipid vesicles containing PtdCho,
PtdSer, PtdIns(3,4,5)P3 and Mg–ATP, and then for
2 minutes at 55°C to inactivate PDK1, the phospholipid
vesicles were unable to activate or phosphorylate
GST–PKBa unless more PDK1 was added (data not
shown). These observations establish that PDK1 does 
not activate GST–PKBa indirectly by converting
PtdIns(3,4,5)P3 to another product that stimulates the
autophosphorylation and autoactivation of GST–PKBa.
Dependence of PDK1 activity on PtdIns(3,4,5)P3
concentration
We next investigated the effect of varying the
PtdIns(3,4,5)P3 concentration on the ability of PDK1 to
activate (Fig. 4a) and phosphorylate (Fig. 4b,c) GST–-
PKBa. These experiments were carried out either by
varying the concentration of PtdIns(3,4,5)P3 whilst main-
taining the concentration of both PtdCho and PtdSer at
100 mM, or by maintaining a 10-fold excess of PtdCho and
PtdSer over PtdIns(3,4,5)P3. Under both conditions, the
concentration of PtdIns(3,4,5)P3 required for half-maximal
activation or phosphorylation was 1–2 mM, with a maximal
effect at 10 mM.
PDK1 phosphorylates Thr308 of PKBa
In order to identify the residue(s) in PKBa phosphorylated
by PDK1, 32P-labelled GST–PKBa which had been phos-
phorylated to 0.4–0.6 moles of phosphate per mole with
PDK1, was digested with trypsin and chromatographed on
a C18 column [15]. One major 32P-labelled peptide was
observed, which eluted at 26% acetonitrile (Fig. 5a). This
peptide, which co-eluted with the 32P-labelled tryptic
phosphopeptide of PKBa containing Thr308 [15], was
found to contain phosphate only on threonine (data not
shown). When this peptide was subjected to solid-phase
sequencing, 32P- label was released after the first cycle of
Edman degradation (Fig. 5b), corresponding to Thr308
[15]. Importantly, no 32P-labelled peptide eluted at the
position corresponding to the tryptic phosphopeptide
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Figure 2
Identification and purification of a PtdIns(3,4,5)P3-dependent protein
kinase, PDK1, which activates GST–PKBa. Following the PEG
precipitation step, PDK activity was chromatographed sequentially on
(a) SP–Sepharose and (b) heparin–Sepharose, and (c) peak 2 from
the latter column was chromatographed on Mono S (see Materials and
methods). PDK activity was assayed in the presence of either
phospholipid vesicles comprising 100 mM phosphatidylcholine
(PtdCho), 100 mM phosphatidylserine (PtdSer), 10 mM D-enantiomer
of sn-1-stearoyl, 2-arachidonyl PtdIns(3,4,5)P3 or vesicles comprising
only 100 mM PtdCho and 100 mM PtdSer (control). The amount of
protein eluted from the Mono S column was too low to see any
absorbance at 280 nm.
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containing Ser473, which elutes at 24% acetonitrile (Fig.
5a; [15]). These data establish that, in vitro, PDK1 phos-
phorylates PKBa at Thr308 only.
Lipid specificity of PDK1
We next studied the ability of a panel of PtdIns deriva-
tives, presented in a vesicle background containing
PtdCho/PtdSer, to activate PDK1. The predominant form
of PtdIns(3,4,5)P3 that occurs naturally is likely to be sn-1-
stearoyl, 2-arachidonyl D-PtdIns(3,4,5)P3 [17] (on the basis
of the structure and fatty acid composition of natural
PtdIns). Synthetic sn-1-stearoyl, 2-arachidonyl D-
PtdIns(3,4,5,)P3 — lipid 1 in Figure 6 — proved highly
effective, activating PDK1 activity 13-fold. By contrast,
the L enantiomer of this lipid induced only a 1.7-fold
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Figure 4
Dependence of PDK1 activity on PtdIns(3,4,5)P3 concentration. The
extent of (a) activation and (b,c) phosphorylation of 0.5 mM
GST–PKBa was assessed (as described in Materials and methods)
after 30 min incubation with PDK1 (12 U ml–1), 10 mM MgAc, 100 mM
g-[32P]ATP and the indicated concentrations of D enantiomer of 1-
stearoyl, 2-arachidonyl PtdIns(3,4,5)P3 either in the presence of a
constant concentration of PtdCho and PtdSer (100 mM of each; b and
open circles in a) or in the presence of a 10-fold molar excess of both
PtdSer and PtdCho over PtdIns(3,4,5)P3 (c and closed circles in a).
The results are presented as the mean ± SEM of two experiments,
each carried out in triplicate.
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Figure 3
PDK1 phosphorylates and activates GST–PKBa. (a) GST–PKBa
(0.5 mM) was incubated with PDK1 (12 U ml–1), 10 mM Mg(Ac)2,
100 mM g-[32P]ATP, and vesicles comprising 100 mM PtdCho,
100 mM PtdSer, 10 mM D enantiomer of sn-1-stearoyl, 2-arachidonyl
PtdIns(3,4,5)P3 in buffer B (see Materials and methods). At various
times, aliquots were removed and assayed either for PKBa activity or
for incorporation of phosphate into GST–PKBa. The activity of
GST–PKBa is presented relative to its activity in control experiments
in which PDK1 was omitted from the reaction mixture.
Phosphorylation was assessed by counting the radioactive
phosphate (32P) incorporated into the GST–PKBa band after
SDS–PAGE. (b) The same assays were carried out as in (a) except
that the effects of omitting either PDK1, ATP, PtdSer/PtdCho, or
PtdIns(3,4,5)P3, heating PDK1 at 55°C for 2 min, or adding 0.5% (by
volume) Triton X-100 on the PDK1 assay at the 60 min time point
were studied. GST–PKBa activity and GST–PKBa phosphorylation
are shown relative to control assays in which PDK1, ATP,
PtdCho/PtdSer and PtdIns(3,4,5)P3 were present. The results are
presented as the mean ± SEM of six determinations (two independent
experiments).
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increase in PDK1 activity, which might be accounted for
by trace contamination with the D enantiomer. Whereas
the enantiomeric configuration of the head group was of
critical importance for activating PDK1, that of the glyc-
erol moiety was not. Thus, sn-2-arachidonyl, 3-stearoyl D-
and L-PtdIns(3,4,5)P3 gave signals which were indistin-
guishable from the sn-1,2-derivatives (16-fold and 2.3-fold,
respectively). The importance of unsaturated fatty acids in
the diacylglycerol moiety is strongly indicated by the fact
that racemic sn-1,2-dilinoleoyl PtdIns(3,4,5)P3 was the
most effective lipid tested (linoleic acid is C18:2), causing
a 36-fold increase in GST–PKBa activity, whereas sn-1,2-
dipalmitoyl D-PtdIns(3,4,5)P3 induced only a 5.5-fold acti-
vation (palmitic acid is C16:0). In each of these
experiments, the phosphorylation of GST–PKBa (Fig. 6b)
correlated with the extent of activation (Fig. 6a).
Interestingly, sn-1,2-dipalmitoyl PtdIns(3,4)P2 (lipid 7 in
Fig. 6) and sn-1,2-dipalmitoyl PtdIns(3,4,5)P3 (lipid 6 in
Fig. 6) activated PDK1 to the same extent , both inositol
phospholipids increasing GST–PKBa activity about 6-fold.
However, PtdIns(3,5)P2 (lipid 8 in Fig. 6), PtdIns(4,5)P2
(lipid 9), PtdIns 4P (lipid 10), PtdIns 3P (lipid 11) and inos-
itol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P4) did not acti-
vate PDK1 or induce the phosphorylation of GST–PKBa.
In the absence of PDK1, none of the PtdIns derivatives
tested induced any activation or phosphorylation of
GST–PKBa (Fig. 6). 
Discussion
The identification and purification of PDK1 was greatly
facilitated by the development of a specific peptide sub-
strate (RPRAATF, in single-letter amino-acid code) for
PKBa [16]. Other substrates used to assay PKB, such as
histone H2B, myelin basic protein and Crosstide, are
phosphorylated by many protein kinases in cell extracts
and therefore obscured the detection of PDK1. The use
of soluble GST–PKBa as a substrate was also important
because PDK1 did not phosphorylate immunoprecipi-
tated  haemagglutinin-tagged PKB effectively. We found
that PDK1 phosphorylated PKBa at Thr308 and
enhanced its activity over 30-fold. As the phosphorylation
of Thr308 of PKBa induced by insulin or IGF1 in vivo is
prevented by inhibitors of PtdIns 3-kinase, and as PDK1
has an absolute requirement for PtdIns(3,4,5)P3 or
PtdIns(3,4)P2, PDK1 is likely to be the enzyme which
phosphorylates PKBa at Thr308 in vivo. PDK1 activity is
unaffected by wortmannin at concentrations of up to
2 mM (data not shown), indicating that PDK1 is not a PI
3-kinase family member.
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Figure 5
PDK1 phosphorylates PKBa at Thr308. 
(a) GST–PKBa was phosphorylated by
incubation for 60 min with PDK1 (12 U ml–1)
and phospholipid vesicles comprising
PtdCho, PtdSer, D enantiomer of 1-stearoyl,
2-arachidonyl PtdIns(3,4,5)P3, and
Mg–g-[32P]ATP (see legend to Fig. 3), and
then alkylated and digested with trypsin. The
digest was applied to a Vydac 218TP54 C18
column (Separations Group, Hesperia,
California) equilibrated in 0.1% (by volume)
trifluoroacetic acid in water. The column was
developed with a linear acetonitrile gradient
(diagonal line) at a flow rate of 0.8 ml min–1
and fractions of 0.4 ml were collected. About
35% of the radioactivity applied to the column
was recovered from the major 32P-containing
peptide which eluted at 26% acetonitrile (the
remainder of the radioactivity eluted as
numerous minor peaks). The elution positions
of PKBa tryptic phosphopeptides which
contain Thr308 and Ser473 are marked [15].
(b) A portion of the major 32P-containing
peptide (500 c.p.m.) from (a) was covalently
coupled to a Sequelon arylamine membrane
and analyzed on an Applied Biosystems 470A
sequencer using the modified programme
described previously [29]. The released
radioactivity was measured after each cycle of
Edman degradation.
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The full activation of PKBa in vitro requires the phos-
phorylation of Ser473 as well as Thr308 [15]. Thus, muta-
tion of either Thr308 or Ser473 to aspartic acid stimulates
PKBa activity about 5-fold but, if both residues are
mutated to aspartic acid, activity is increased 18-fold. Sim-
ilarly, phosphorylation of Ser473 stimulates PKBa activity
7-fold, but if phosphorylation of Ser473 is combined with
mutation of Thr308 to aspartic acid, then activity is
increased 25-fold [15]. PKBa that has been partially acti-
vated either by phosphorylation of Thr308 or by mutation
of this residue to aspartic acid does not become phospho-
rylated at Ser473 in vitro upon incubation with Mg–ATP
in the presence of PtdIns(3,4,5)P3 ([15] and Fig. 5), indi-
cating that Ser473 is unlikely to be autophosphorylated by
PKBa itself. Ser473 can be phosphorylated in vitro by
mitogen-activated protein kinase-activated protein kinase-
2 (MAPKAPK2), but this enzyme cannot mediate the
insulin-induced or IGF1-induced phosphorylation of
PKBa at Ser473 for reasons we have discussed previously
[15]. As the insulin/IGF1-induced phosphorylation of
Ser473 is prevented by inhibitors of PI 3-kinase, this
residue may be phosphorylated by a distinct 3-phospho-
inositide-dependent protein kinase (perhaps PDK2; see
Fig. 7). The Ser473 kinase does not appear to be the
PtdIns(3,4,5)P3-dependent peak 1 activity seen after the
heparin–Sepharose PDK1 purification step (Fig. 2b),
however, because this enzyme also phosphorylates PKB at
Thr308 (data not shown). The peak 1 activity may be a
proteolytic fragment from peak 2 (or vice versa), or maybe
another isoform of PDK1. It is also possible that
PtdIns(3,4,5)P3/PtdIns(3,4)P2 activates the Ser473 kinase
indirectly. For example, the phosphorylation of Ser473
may be dependent on the binding of
PtdIns(3,4,5)P3/PtdIns(3,4)P2 to the pleckstrin homology
(PH) domain of PKB [18,19] (but see below). Alterna-
tively, the Ser473 kinase may be activated by PDK1. The
mechanism we propose for the activation of PKBa follow-
ing insulin stimulation is shown schematically in Figure 7.
The activation of PDK1 by PtdIns(3,4,5)P3 is extremely
specific, because only D enantiomers of PtdIns(3,4,5)P3
are effective and many other PtdIns phospholipids are not.
Although the enantiomeric configuration of the glycerol
moiety is not important, the presence of one or more
unsaturated fatty acids greatly influences the extent of
activation of PDK1 by PtdIns(3,4,5)P3 analogues (Fig. 6).
Since unsaturated fatty acids discourage tight packing of
adjacent phospholipid molecules, it is possible that this
arrangement allows for more efficient interaction between
membrane-inserted PtdIns(3,4,5)P3 and its effectors,
perhaps explaining for the first time the biological signifi-
cance of the unusual fatty acid composition of inositol
phospholipids.
PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 have no effect on the
activity of PKBa under conditions where these inositol
phospholipids activate PDK1 strongly (Fig. 6), consistent
with our previous findings [18]. This observation, together
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Figure 6
PDK1 is activated specifically and
stereospecifically by PtdIns(3,4,5)P3 and
PtdIns(3,4)P2 lipids. GST–PKBa was
incubated for 30 min at 30°C with
Mg–g-[32P]ATP and phospholipid vesicles
containing 100 mM PtdCho, 100 mM PtdSer,
and various PtdIns lipids (numbered 1–11;
see below) or Ins(1,3,4,5)P4, each at a final
concentration of 10 mM, in the presence or
absence of PDK1. Reactions were terminated
by the addition of 1% (by volume) Triton X-
100 to the assay. (a) The activity of
GST–PKBa was determined as described in
Materials and methods. The results are
presented as the mean fold activation of
GST–PKBa ± SEM for six to eight
determinations (three independent
experiments). (b) The phosphorylation of
GST–PKBa was assessed by
autoradiography of the Coomassie-blue-
stained band corresponding to GST–PKBa
(see Fig. 1 legend). Lipids 1 and 2 are the D
and L enantiomers of sn-1-stearoyl, 2-
arachidonyl PtdIns(3,4,5)P3, respectively, and
lipids 3 and 4 are the D and L enantiomers of
sn-2-arachidonyl, 3-stearoyl PtdIns(3,4,5)P3,
respectively. Lipid 5 is racemic sn-1,2-
dilinoleoyl PtdIns(3,4,5)P3. The remaining
lipids are all D enantiomers; lipid 6 is sn-1,2-
dipalmitoyl PtdIns(3,4,5)P3; lipid 7 is sn-1,2-
dipalmitoyl PtdIns(3,4)P2; lipid 8 is sn-1,2-
dipalmitoyl PtdIns(3,5)P2. Lipid 9 is
PtdIns(4,5)P2 and lipid 10 is PtdIns 4P; both
are purified lipids derived from Folch fraction
type-I brain extract. Lipid 11 is sn-1,2-
dipalmitoyl PtdIns-3P. IP4 is Ins(1,3,4,5)P4.
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with the finding that the activation of PKBa by insulin or
IGF1 results from its phosphorylation at Thr308 and
Ser473 [15], appears to exclude direct activation of PKBa
by 3-phosphoinositides as a mechanism in vivo. Our results
disagree with recent reports which have claimed that
PKBa is activated directly by PtdIns(3,4)P2 [19–21]. Cont-
amination of PKBa preparations with PDK1 activity may
explain this discrepancy; it is worth recalling that the acti-
vation of phosphorylase kinase by cyclic AMP [22] was
later shown to result from contamination with a separate
cyclic AMP-dependent protein kinase [23]. It has also been
reported that PKBa is inhibited by PtdIns(3,4,5)P3 [19,21],
but none of the four PtdIns(3,4,5)P3 derivatives we tested
inhibited the basal PKBa activity at all, while all four were
capable of activating PDK1. It is possible that the synthetic
PtdIns(3,4,5)P3 used in previous studies [19,21] contains
impurities that inhibit PKBa and/or PDK1.
Although PKB is not activated directly by PtdIns(3,4,5)P3
or PtdIns(3,4)P2, it does bind these inositol phospholipids
with micromolar affinity [18,19], by the amino-terminal
PH domain [19]. In contrast, PKB binds PtdIns(4,5)P2
with a 10-fold lower affinity and does not bind to other
inositol phospholipids tested [18,19]. These findings raise
several interesting possibilities. Firstly, the interaction of
PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 with PKB may alter
its conformation in such a way as to facilitate phosphoryla-
tion by PDK1 and the Ser473 kinase. Secondly, the forma-
tion of PtdIns(3,4,5)P3 and/or PtdIns(3,4)P2 in the plasma
membrane may recruit PKB to this membrane, also facili-
tating its activation by PDK1 and the Ser473 kinase.
Neither of these mechanisms appears to be essential for
the activation of PKB in vivo, however, because a mutant
lacking the PH domain can still be activated at least as
well as wild-type PKB in response to insulin [6,24]. Alter-
natively, recruitment of PKB to the plasma membrane
could facilitate the phosphorylation of membrane-bound
PKB substrates. It should be noted, however, that we
purified PDK1 from the cytosol of skeletal muscle. It will
clearly be important to examine whether PDK1 localizes
to the plasma membrane when cells are stimulated with
agonists which trigger a rise in the concentration of
PtdIns(3,4,5)P3 and PtdIns(3,4)P2.
Materials and methods
Materials
PtdSer (pig brain) was purchased from Doosan Serdary Research Lab-
oratories (New Jersey, USA) and sn-1-stearoyl, 2-arachidonyl PtdCho
from Sigma (Poole, UK). PtdIns 4P and PtdIns(4,5)P2 were purified as
described previously from Folch fraction type-1 extract of bovine brain
(Sigma) [25]. Synthetic sn-1,2-dipalmitoyl analogues of PtdIns(3,4,5)P3,
PtdIns(3,4)P2, PtdIns(3,5)P2 and PtdIns 3P were made as described
previously [18]. Synthetic D and L enantiomers of sn-1-stearoyl, 2-
arachidonyl PtdIns(3,4,5)P3, sn-2-arachidonyl, 3-stearoyl
PtdIns(3,4,5)P3 and the racemic mixture of sn-1-linoleoyl-2-linoleoyl
PtdIns(3,4,5)P3 were synthesized from inositol (P.R.J.G. and C.B.R.,
unpublished methods). All phospholipids were 97–98% pure. Synthetic
phosphatidylinositol bisphosphates were stored at –20°C as solutions
in dimethyl sulphoxide (DMSO), and phosphatidylinositol trisphosphates
were stored in either DMSO or water. All other phospholipids were
stored in chloroform–methanol solvents. The peptide used to assay
PKBa, (RPRAATF) [16] and TTYADFIASGRTGRRNAIHD (the specific
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Figure 7
Proposed mechanism by which insulin induces the activation of PKBa.
Activation of the insulin receptor by insulin causes the receptor to
phosphorylate itself at several tyrosine residues. This leads to docking
of insulin receptor substrate-1 (IRS-1) and IRS-2 and their
phosphorylation at multiple tyrosine residues by the insulin receptor.
Several phosphorylated tyrosine residues on IRS-1 and IRS-2 then
interact with SH2 domains on the p85 subunit of PI 3-kinase, leading
to the recruitment of the p110 catalytic subunit of PI 3-kinase to cell
membranes, and its activation [30]. PI 3-kinase then phosphorylates
PtdIns(4,5)P2 at the D-3 position of the inositol ring, resulting in the
formation of the second messenger PtdIns(3,4,5)P3, levels of which (in
a typical cell) rise from 0.1% to 1–2% of the PtdIns(4,5)P2 content in
the plasma membrane [30]. PtdIns(3,4,5)P3 interacts with and
activates PDK1, which partially activates PKBa by phosphorylating
PKBa at Thr308. Maximal activation of PKBa also requires the
phosphorylation of Ser473 by an unknown kinase. The insulin-induced
phosphorylation of Ser473, like the phosphorylation of Thr308, is
prevented by inhibitors of PI 3-kinase [15], suggesting that Ser473
may be phosphorylated by a distinct 3-phosphoinositide-dependent
protein kinase (PDK2). The Ser473 kinase may, however, be activated
indirectly by 3-phosphoinositides by mechanisms discussed in the text.
For this reason, the pathway from PtdIns(3,4,5)P3 to the phosphory-
lation of Ser473 by the putative PDK2 is shown by broken lines. In
skeletal muscle, the activation of PKBa may increase the rate of
glucose uptake [11] and glycogen synthesis [9] and stimulate protein
translation [10]. In neurons and other cells, PKBa activation may
provide a survival signal by suppressing apoptosis [12,13].
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peptide inhibitor of cyclic-AMP-dependent protein kinase, termed PKI)
were synthesized by F. Barry Caudwell (Medical Research Council
Protein Phosphorylation Unit, Dundee) on an Applied Biosystems 431A
peptide synthesizer, and their concentrations were determined by quan-
titative amino-acid analysis. Glutathione–Sepharose was purchased
from Pharmacia (Milton Keynes, UK) and alkylated trypsin from Promega
(Southampton, UK).
Buffer solutions 
Buffer A contained 50 mM Tris/HCl pH 7.5, 1 mM EDTA, 1 mM EGTA,
1% (by volume) Triton X-100, 1 mM sodium orthovanadate, 10 mM
sodium b-glycerophosphate, 50 mM NaF, 5 mM sodium pyrophos-
phate, 1 mM Microcystin-LR, 0.27 M sucrose, 1 mM benzamidine,
0.2 mM phenylmethylsulphonyl fluoride (PMSF), 10 mg ml–1 leupeptin
and 0.1% (by volume) 2-mercaptoethanol. Buffer B contained 50 mM
Tris/HCl pH 7.5, 0.1 mM EGTA, 0.03% (by volume) Brij-35, 0.27 M
sucrose and 0.1% (by volume) 2-mercaptoethanol. Buffer C contained
50 mM Tris/HCl pH 7.5, 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 0.1%
(by volume) 2-mercaptoethanol, 0.1 mM PMSF and 1 mM benzamidine.
Expression of GST–PKBa in 293 cells
The DNA sequence encoding PKBa was subcloned into the eukaryotic
expression vector PEBG2T which has been used to overexpress GST-
fusion proteins in eukaryotic cells under an EF1a promoter [26]. A poly-
merase chain reaction (PCR) was set up to generate a full-length cDNA
encoding the PKBa gene with a BamH1site at the 5′ end of the cDNA
that was in frame with the GST sequence of the PEBG2T vector and
the ATG initiation codon of PKBa, and a KpnI site at the 3′ end, using
the human PCMV5–HA–PKBa plasmid [15]. The DNA sequence of the
BamH1–KpnI cDNA fragment was checked and then subcloned into
the unique BamH1–KpnI restriction sites on the pEBG2T expression
vector. In order to prepare GST–PKBa, forty 10 cm diameter dishes of
human embryonic kidney 293 cells were cultured and each dish trans-
fected with 20 mg GST–PKBa expression construct using the modified
calcium phosphate method described previously for overexpression of
haemagglutinin-tagged PKBa in 293 cells [15]; 24 h after transfection,
the cells were serum starved for 16 h and each dish of cells was lysed in
1 ml ice-cold Buffer A. The 40 lysates were pooled, centrifuged at 4°C
for 10 min at 13 000 g and the supernatant incubated for 60 min on a
rotating platform with 800 ml glutathione–Sepharose previously equili-
brated in Buffer A. The suspension was centrifuged for 1 min at 3000g,
the beads washed three times with 10 ml Buffer A containing 0.5 M
NaCl, and then a further 10 times with 10 ml Buffer B to ensure com-
plete removal of all the Triton X-100 which interferes with the activation
of GST–PKBa by PDK1; Figure 3b. GST–PKBa was eluted from the
resin at ambient temperature with three 1 ml portions of Buffer B con-
taining 20 mM glutathione pH 8.0. The combined eluates (0.65 mg
protein per ml) were divided into aliquots, snap frozen in liquid nitrogen,
and stored at –80°C.
Preparation of phospholipid vesicles
Phospholipid vesicles comprising 1 mM PtdCho, 1 mM PtdSer and
0.1 mM PtdIns lipids were prepared, dried to a film under vacuum and
resuspended with vortexing in 10 mM Hepes, pH 7.3. The cloudy solu-
tion of multilamellar and large unilamellar vesicles was bath-sonicated
for 20 min, after which a clearer suspension of smaller unilamellar vesi-
cles was obtained. Solutions were stored at 4°C at concentrations 10-
fold higher than those required in the assay, and used within 2–4 days. 
Purification of PDK1 from rabbit skeletal muscle 
On day 1, a female New Zealand White rabbit was killed with a lethal
dose of sodium pentobarbitone. Skeletal muscle from the hind limbs
and back (500 g) was excised rapidly and placed on ice. All subsequent
steps were carried out at 0–4°C. The muscle was minced, homoge-
nized in 2.5 volumes of 25 mM Tris/HCl pH 7.5, 4 mM EDTA, 2 mM
EGTA, 50 mM NaF, 0.1% (by volume) 2-mercaptoethanol, 0.1 mM
PMSF and 1 mM benzamidine and centrifuged for 30 min at 4200g.
The supernatant was filtered through glass wool and poured through 
a Buchner funnel containing 10 g of QAE (quaternany amino
ethyl)–Sephadex equilibrated in Buffer C. The column was washed with
1 l Buffer C containing 50 mM NaCl, and washed with 700 ml Buffer C
containing 0.2 M NaCl to elute PDK1. A 50% (by mass) solution of
polyethylene glycol (PEG) was added to the eluate to bring the final
concentration of PEG to 4%. After stirring on ice for 60 min, the sus-
pension was centrifuged for 15 min at 10 000 g. The supernatant was
decanted and made up to 15% PEG by further addition of 50% (by
mass) PEG. After stirring for a further 60 min on ice, the suspension
was again centrifuged for 15 min at 10 000 g. The supernatant was dis-
carded and the precipitate dissolved in 50 ml ice-cold Buffer B, filtered
through a 0.25 mm filter and then chromatographed on an
SP–Sepharose column (11 × 1.6 cm) equilibrated in Buffer B. The
column was developed with a 300 ml linear gradient of NaCl to 0.5 M at
a flow rate of 3 ml min–1 and 6 ml fractions were collected (Fig. 2a). The
active fractions were pooled and applied directly onto a 5 ml
heparin–Sepharose column (HiTrap), equilibrated in Buffer B containing
0.1 M NaCl. The column was developed with a 90 ml linear salt gradient
to 0.9 M NaCl at a flow rate of 2 ml min–1 and fractions of 1 ml were col-
lected. PDK activity eluted as 2 peaks; peak 1, comprising ~30% of the
activity, eluted at 0.5 M NaCl, whereas peak 2, comprising ~70% of the
activity, eluted at 0.7 M NaCl (Fig. 2b). On day 2, the active fractions of
peak 2 were pooled, concentrated to 0.2 ml by ultrafiltration, diluted to
2.0 ml in Buffer B, and loaded onto a Mono S column (5 cm × 1.6 mm)
equilibrated in Buffer B. The column was developed with a 4.0 ml linear
gradient of salt to 0.15 M MgCl2 at a flow rate of 0.2 ml min–1, and
0.1 ml fractions were collected. Fractions containing PDK activity
(PDK1) were aliquoted, snap-frozen in liquid nitrogen, and stored at
–80°C. No significant loss of activity occurred upon thawing.
Assay of PDK1
The assay was carried out in two stages; in the first stage, GST–PKBa
was incubated with PDK1 in the presence of Mg–ATP and phospholipid vesi-
cles to permit activation of GST–PKBa. In the second stage, the solu-
tion was made up to 0.5 % (by volume) Triton X-100 (which completely
inhibits phosphorylation and activation of GST–PKBa by PDK1 without
affecting GST–PKBa activity; see Fig. 3b), together with Mg–g-
[32P]ATP, and the specific PKBa substrate peptide RPRTAAF [16].
In Stage 1, an 18 ml reaction mixture was set up containing 50 mM
Tris/HCl pH 7.5, 0.1 mM EGTA, 0.1% (by volume) 2-mercaptoethanol,
0.1 mM EGTA, 2.5 mM PKI, 1 mM microcystin-LR, 10 mM Mg(Ac)2,
100 mM unlabelled ATP, 0.6 mM GST–PKBa, 100 mM PtdSer,
100 mM PtdCho in the presence or absence of 10 mM PtdIns(3,4,5)P3.
The assay was initiated by the addition of 2 ml PDK1 and, after incuba-
tion for 30 min at 30°C, stage 2 of the assay was initiated by the addi-
tion of 30 ml of a mixture containing 50 mM Tris/HCl pH 7.5, 0.1 mM
EGTA, 0.1% (by volume) 2-mercaptoethanol, 0.1 mM EGTA, 2.5 mM
PKI, 1 mM microcystin-LR, 10 mM Mg(Ac)2, 100 mM g-[32P]ATP
(200–400 c.p.m. pmol–1), 100 mM of the peptide RPRTAAF and
1.25% (by volume) Triton X-100. After 10 min at 30°C, the reactions
were terminated by spotting the reaction mixture onto p81 phosphocel-
lulose paper. The papers were washed in phosphoric acid and
analysed as described previously [27]. A control reaction in which
GST–PKBa was omitted was taken as the blank and was always less
than 5% of the activity measured in the presence of GST–PKBa. The
basal GST–PKBa activity is the activity measured in the absence of
PDK1. One unit (U) of PDK1 activity was defined as the amount
required to increase the basal activity of GST–PKBa by 1 unit of activ-
ity; 1 unit of GST–PKBa activity was the amount of enzyme required to
catalyze the phosphorylation of 1 nmol of the peptide RPRTAAF in
1 min. The assays were linear with time, up to a final concentration of
2 U ml–1 PDK1 activity in the assay.
Phosphorylation of GST–PKBa by PDK1
The incubations were identical to those in stage 1 described above,
except that g-[32P]ATP (200–400 c.p.m. pmol–1) was used instead of
unlabelled ATP. The reactions were terminated by making the solution
1% (by mass) SDS. The samples were run on a 7.5% SDS–poly-
acrylamide gel and, after staining with Coomassie blue, the gels were
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autoradiographed. The Coomassie-blue-staining bands corresponding
to GST–PKBa were excised and the radioactivity associated with each
band was quantified.
Mapping the site on GST–PKBa phosphorylated by PDK1
GST–PKBa was phosphorylated in the presence of the D enantiomer
of sn-1-stearoyl, 2-arachidonyl PtdIns(3,4,5)P3 as described above,
except that the scale of the reaction was increased 10-fold and the
specific activity of the g-[32P]ATP was increased to
1500 c.p.m. pmol–1. The reaction was stopped by the addition of SDS
and 2-mercaptoethanol to final concentrations of 1% (by mass) and
1% (by volume), respectively, and heated for 5 min at 95°C. After
cooling to ambient temperature, 4-vinylpyridine was added to a con-
centration of 2.5% (by volume) and the sample left on a shaking plat-
form for 1 h at 30°C to alkylate cysteine residues. The sample was then
electrophoresed on a 7.5% SDS–polyacrylamide gel, and the 32P-
labelled GST–PKBa eluted from the gel and digested with trypsin as
described previously [15].
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